Monkeypox Update for Providers, Aug. 12, 2022

Monkeypox Update for Providers

Aug. 12, 2022

Jynneos Vaccine Eligibility

Following the EUA decision earlier this week by the FDA to expand access with an alternate dosing regimen, Alaska is now opening eligibility to include Tier 3. A NEW webpage Monkeypox Info for Health Care Providers webpage is now live. Please review the webpage for important information about testing, reporting and vaccination.

Please review the tiers for Jynneos eligibility below. If you have patients who meet the below criteria, please reach out to a local public health center for vaccine availability.

Tier 1: Post-exposure prophylaxis vaccination (PEP) for people (regardless of gender) who have had a documented/notified exposure to someone with monkeypox, including:

  • People who have been identified by public health authorities as a contact with high or intermediate risk exposure to monkeypox.
  • People who have been alerted that they may have been exposed to monkeypox, even if they are not contacted by a public health authority (e.g., a person who received a notification from a recent sexual partner or an anonymous notification of exposure).

Tier 2: Expanded post-exposure prophylaxis vaccination (PEP++) for people potentially at increased risk for monkeypox even if they have not had a documented/notified exposure to someone with monkeypox, including:

  • Gay, bisexual, or other men or transgender people who have sex with men AND
  • Have had multiple or anonymous sexual partners in the past 14 days.

Tier 3: Expanded post-exposure prophylaxis vaccination (PEP++) / Pre-exposure prophylaxis vaccination (PrEP) for people potentially at increased risk for monkeypox even if they have not had a documented/notified exposure to someone with monkeypox and may not have had an exposure specifically within the past 14 days, including:

  • Gay, bisexual, or other men or transgender people who have sex with men AND
  • Has had multiple or anonymous sexual partners in the past 6 months